Compare BIO-TECHNE Corp (TECH) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Real Estate Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Vanguard Real Estate Index Fund ETF trades at $96.4. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Real Estate Index Fund ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VNQ | |
|---|---|---|
Market Cap | $11.24B | — |
Sector | Health | — |
52-Week High | $72.29 | $100.95 |
52-Week Low | $43.31 | $87.00 |
Enterprise Value | $11.32B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VNQ trades at $98.43, up 0.4% with neutral technical signals and bullish moving averages. The ETF shows mixed momentum with RSI at oversold levels near 18.24. Recent institutional activity includes Bank of America and Financial Advisory Corp reducing positions. Dividend yield remains competitive amid Federal Reserve rate cuts supporting real estate valuations.
Outlook remains balanced with technical support at $97-$98 and resistance at $99-$100. Rate cuts provide tailwinds, but REIT-specific risks and sector underperformance versus broader market warrant caution. The neutral sentiment reflects divided analyst views on real estate ETF opportunities versus active management alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
